Iporanga Ventures

Iporanga Ventures is a Sao Paulo seed firm with one of the more credible early-track records in Brazilian venture: the team was an early backer of Loggi and QuintoAndar before either name was inevitable, and that pattern of conviction in marketplace and infrastructure plays now extends into healthtech and applied AI. The fund writes seed and Series A checks generally in the $250K to $1M range, which positions it as a meaningful first or second institutional ticket rather than a Series A lead for capital-intensive companies. Geography matters here. Iporanga is fundamentally a Brazil-focused investor with a deep network across the Sao Paulo founder community, and the value it adds is concentrated in helping companies navigate the specific operational realities of Brazilian healthcare: ANS regulation, the SUS-versus-private payer split, the integration burden with hospital ERPs, and the talent market for clinical and engineering teams. Founders solving real workflow problems for Brazilian providers, payers, or pharmacies, with software that has measurable adoption metrics, are the natural fit. The wrong fit is a US-style horizontal AI platform with no localization plan or a deep-science biotech that needs $20M to reach a clinical milestone. The right entry path is through Brazilian founder networks, particularly people who built or scaled marketplace and consumer-internet companies in the country during the 2014 to 2020 window. Iporanga will also receive inbound from local accelerator alumni and from co-investors at funds like Maya, Canary, and Monashees, and a warm referral from any of those partners materially raises the probability of a real conversation. When pitching, lead with the unit-economic story specific to Brazil and a clear thesis on which AI capability genuinely changes either cost-to-serve or clinical outcomes in your loop, not a generic pitch about LLMs in healthcare. Concrete metrics matter more than narrative; the partners are commercially minded and react better to a chart than a manifesto. Caveats: Iporanga’s check size means founders pursuing a $5M Series A will need to organize a syndicate, and the firm’s reputation, while strong locally, does not carry the same weight with US later-stage funds as a tier-one Brazilian growth investor. Use Iporanga as the partner who helps you build conviction inside Brazil, then layer in international capital when the metrics earn it. For early healthtech and AI founders operating in Portuguese-speaking Latin America, this is a credible early call to take.